$PTCT News

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals

PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics Q2 Earnings Call Highlights

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates